News Search Results
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
multiple ADC and novel DC assets in clinical or preclinical research stage.About Windward Bio AGWindward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced
More news about: Harbour BioMed
Mar 21, 2026, 12:42 ET Sind hochwertige Proteine kein Luxus mehr? Auf der FIC 2026 zeigt Angel Yeast neue Wege auf
um einen Konsens zu erzielen und den Wissensaustausch zu fördern. Im Bereich der Produktion hat Angel Yeast im vergangenen November im Baiyang Biotechnology Park in Yichang eine neue Produktionslinie für Hefeproteine in Betrieb genommen, wodurch die jährliche Produktionskapazität um mehr als 10.000 Tonnen
More news about: Angel Yeast
Mar 21, 2026, 11:38 ET 고품질 단백질, 더 이상 사치품이 아니다? 엔젤 이스트, FIC 2026에서 그 방법을 제시하다
Symposium on Yeast Protein Science and Technology)을 개최하고, 산업 백서를 발표해 공감대를 형성하고 지식 공유를 촉진할 계획이다. 생산 측면에서는 지난해 11월 이창 바이양 생명공학 단지(Yichang Baiyang Biotechnology Park)에 신규 효모 단백질 생산라인을 가동하며 연간 1만 톤 이상의 생산능력을 추가했다. 급증하는 시장 수요에 대응하기 위해 엔젤 이스트는 이미 추가 증설도 계획하고 있으며, 이를 통해 공급 역량을 강화할 방침이다.엔젤 이스트는 시장 개발 측면에서도
More news about: Angel Yeast
Mar 21, 2026, 11:22 ET 高品質のプロテインはもはやぜいたく品ではない？Angel Yeast、FIC2026でその取り組みを示す
Yeastは、世界の酵母タンパク質業界における重要な推進役としての地位をさらに強固なものにしています。同社は引き続き研究開発投資を拡大するとともに、腸の健康とスポーツ栄養に関する応用研究で国際的な研究機関との連携を進めています。また同社は今年4月、酵母タンパク質の科学と技術に関する第2回国際シンポジウムを開催し、業界コンセンサスの形成と知見共有の促進を目的とした業界白書を発表する予定です。生産面では、Angel Yeastは昨年11月、宜昌のBaiyang Biotechnology Parkに新たな酵母タンパク質生産ラインを稼働させ、年間1万トンを超える生産能力を追加しました。急増する市場需要に対応するため、同社は供給能力強化に向けたさらなる拡張もすでに計画しています。同社はまた、市場展開における大きな前進も発表しました。Angel YeastのInternational
More news about: Angel Yeast
Mar 20, 2026, 12:05 ET Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
LinkedIn.About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Mar 20, 2026, 11:53 ET /C O R R E C T I O N -- The Galien Foundation/
India Awards Committee, representing the biomedical industry and academia, recognized this year's award winners in the following categories: "Best Biotechnology Product", "Best Digital Health Solution", "Best Medical Technology", "Best Pharmaceutical Product", "Best Product for Rare/Orphan Diseases", "Best
More news about: The Galien Foundation
Mar 20, 2026, 11:11 ET 'Miracle of Life' Dr. George Delgado Joins Aureum Therapeutics, Inc. in Pioneering Transformative and Life-Saving Treatments
Biotechnology Company Explores Intricate Mechanisms of Pregnancy to Develop Groundbreaking Treatments for Cancer and Recurrent MiscarriageSAN DIEGO, March 20, 2026 /PRNewswire/ -- Aureum Therapeutics, Inc., a
More news about: Aureum Therapeutics
Mar 20, 2026, 10:34 ET Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026
consensus and encourage knowledge sharing. On the production front, Angel Yeast commissioned a new yeast protein production line at its Baiyang Biotechnology Park in Yichang last November, adding an annual production capacity exceeding 10,000 tons. To meet surging market demand, the company has already
More news about: Angel Yeast
Mar 20, 2026, 10:22 ET Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026
consensus and encourage knowledge sharing. On the production front, Angel Yeast commissioned a new yeast protein production line at its Baiyang Biotechnology Park in Yichang last November, adding an annual production capacity exceeding 10,000 tons. To meet surging market demand, the company has already
More news about: Angel Yeast
Mar 20, 2026, 10:00 ET Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
diseases. It is wholly owned by Nektar Therapeutics.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 20, 2026, 07:30 ET Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation
More news about: Earendil Labs
Mar 20, 2026, 05:23 ET PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou
application.Opening day saw the unveiling of close to 50 new product launches, with exhibitors presenting developments across ingredient technologies, biotechnology, formulation systems, testing services, packaging materials, and AI-enabled applications — reflecting strong momentum in performance-driven, sustainable,
More news about: Reed Sinopharm Exhibitions (RSE)
Mar 20, 2026, 04:59 ET PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou
application.Opening day saw the unveiling of close to 50 new product launches, with exhibitors presenting developments across ingredient technologies, biotechnology, formulation systems, testing services, packaging materials, and AI-enabled applications — reflecting strong momentum in performance-driven, sustainable,
More news about: Reed Sinopharm Exhibitions (RSE)
Mar 20, 2026, 04:51 ET Precision Fermentation Market to Reach USD 57.1 Billion by 2032, Driven by Sustainable Protein Innovation and Biotech Advancements, Reports MarkNtel Advisors
the total market share in 2026. The region's leadership is supported by strong regulatory frameworks for novel foods, increasing investments in biotechnology innovation, and a well-established ecosystem of startups and research institutions focused on sustainable protein production. Additionally, favorable
More news about: MarkNtel Advisors
Mar 19, 2026, 21:00 ET D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 19, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation
More news about: D3 Bio
Mar 19, 2026, 20:00 ET Taiwan hosts APEC Workshop Highlights Innovative Technologies for Low-Carbon Food Supply Chains
Deputy Director General of FIRDI, presented innovations in food manufacturing process technology. Dr. Yi-Chung Lai, R&D Consultant at Biozyme Biotechnology, and Dr. Chin-Chu Chen, General Manager of Grape King Bio, discussed green fermentation processing and product development practices. Marcie Chan,
More news about: Food Industry Research and Development Institute (FIRDI)
Mar 19, 2026, 17:40 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 19, 2026, 17:14 ET Blue Water Acquisition Corp. IV, Sponsored by New York Based Investor, Joseph Hernandez, Announces Pricing of $125 Million Initial Public Offering
acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the biotechnology, healthcare and technology sectors.BTIG, LLC is serving as the sole book-running manager of the offering.A registration statement
More news about: Blue Water Acquisition Corp. IV
Mar 19, 2026, 16:00 ET Curis Provides Fourth Quarter 2025 Business Update
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business
More news about: Curis, Inc.
Mar 19, 2026, 11:00 ET PSI Reduces Clinical Trial Site Identification From Weeks to Minutes Using AI Agent Powered by Arango Contextual Data Platform
(CRO) dedicated to delivering quality and on-time clinical research services across numerous therapeutic areas. PSI supports pharmaceutical and biotechnology companies worldwide with end-to-end clinical trial conduct.About ArangoArango delivers a unified, natively multimodel contextual
More news about: Arango
Mar 19, 2026, 10:30 ET Poultry Diagnostics Market worth $0.25 billion by 2031 | MarketsandMarkets™
Bio-Rad Laboratories, Inc. (US), BioChek (Netherlands), GD (Netherlands), INDICAL BIOSCIENCE GmbH (Germany), Shenzhen Bioeasy Biotechnology, Inc. (China), Ring Biotechnology Co., Ltd. (China), Bio-X Diagnostics S.A. (Belgium), MEGACOR Diagnostik GmbH (Austria), Gold Standard Diagnostics (Germany), and
More news about: MarketsandMarkets
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
InstitutionsOthersRelated Reports of Biotechnology Market Reports
More news about: Persistence Market Research Pvt. Ltd.
Mar 19, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
REO 033 expects to open its first site next month, with preliminary data targeted for year-end 2026.Oncolytics is a clinical-stage biotechnology company that has spent years building a scientific case for pelareorep across multiple tumor types. Across anal cancer, pancreatic cancer, and now
More news about: USA News Group
Mar 19, 2026, 09:57 ET Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
into an execution-oriented national preparedness platform.About Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefense applications. By integrating high-throughput vertebrate screening
More news about: Lunai Bioworks Inc.